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ABSTRACT
Ethambutol is a bacteriostatic antimicrobial agent used in the treatment of tuberculosis. Optic neuropathy is a potentially severe side effect of 
ethambutol, which is dose related. Ethambutol-induced optic neuropathy (EON) incidence is 15%, 5%, and 1% when taken at 50, 25, and 15 mg/kg/day, 
respectively, for 3 months. Hence, we report a case of bilateral EON in 20-year-old female after 1 month of exposure to 15 mg/kg/day of ethambutol 
for tubercular meningitis. Ophthalmologic examination revealed bilateral ill sustained pupillary reactions and optic disc pallor. Deranged color vision 
test and scotomas on Goldmann perimetry in both eyes, aided in diagnosis.
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INTRODUCTION
Ethambutol hydrochloride is a bacteriostatic antimicrobial agent 
used as a first line defense against mycobacterium tuberculosis (TB). 
It acts as a chelating agent that disrupts one of the metal-containing 
enzymes in the nucleic acid structures of mycobacteria by preventing 
incorporation of mycolic acid into the mycobacterial cell wall and its 
toxicity involves same mechanism [1]. Optic neuropathy has been well 
described among toxic effects of ethambutol, causing decreased visual 
acuity (65.4%), abnormal visual fields (65.4%), abnormal color vision 
(61.5%), and optic disc pallor (38.5%) [2]. This reaction is dose related 
and observed in 15% of patients receiving ethambutol 50 mg/kg/day, 
5% of patients receiving 25 mg/kg/day, and <1% of patients receiving 
a daily dose of 15 mg/kg [3]. Optic nerve involvement is a rare side 
effect of isoniazid (INH) [4]. We hereby report a rare case of bilateral 
ethambutol-induced optic neuropathy (EON) when taken at a very low 
dose of 15 mg/kg/day for 1 month and whose symptoms got completely 
reversed on discontinuation of ethambutol.
CASE REPORT
A 20-year-old female presented with sudden diminution of vision in 
both eyes since 10-15 days. It started as mild blurring of vision with, 
inability to recognize colors properly, difficulty in reading small letters 
and progressed rapidly. She has been on ethambutol 15 mg/kg/day 
along with the other Category I anti-tubercular treatment (ATT) drugs 
for 2 months in view of TB meningitis with tuberculoma.
Her visual acuity was 6/60, N10 in the right eye and 6/18, N8 in the left 
eye. Examination of both eyes revealed ill sustained pupillary reactions 
with normal intraocular pressure. Color vision test with Ishihara charts 
was deranged in both eyes. Fundus examination revealed bilateral 
temporal pallor with the blurring of temporal margins and nonspecific 
pigmentary changes in the macular region (Fig. 1). Goldmann perimetry 
showed centrocecal scotoma with peripheral field constriction in both 
eyes.
Ethambutol was discontinued without intervening other Category I ATT 
drugs and supplemented with oral vitamin B1, B5, B6, and B12 along 
with oral steroids (1 mg/kg) for 2 weeks. On review 2 weeks later visual 
acuity improved to 6/6, N6 in both eyes with a normal color vision test, 
fundus picture, and Goldmann perimetry.
DISCUSSION
Optic neuropathy is a well-documented toxic effect of ethambutol. 
Although INH may also be responsible, EON is more widely 
recognized [5]. A survey of 37 ethambutol toxicity cases conducted by 
Danish Board of Adverse Reactions showed preponderance to elderly 
and females [6]. The occurrence of ocular toxicity is dose related, loss 
of vision most likely to occur in patients receiving 25 mg/kg/day or 
more. However, vision loss has been documented in approximately 
1% of patients receiving the recommended therapeutic dose of 
15-25 mg/kg/day [7]. This rarely occurs before 2 months in patients 
who have been on treatment, with 7 months being the average [8]. 
Most of the cases, vision is reversible with stoppage of ATT, rarely it is 
irreversible [9]. In our case report, a patient aging 20 years developed 
EON with very low dose of 15 mg/kg/day for the 1 month duration. 
With respect to above literature, EON at such a young age, with such low 
dosage and short duration, is very rare.
CONCLUSION
It is important for the clinicians to be aware of the rapid onset of EON 
even with a low dosage of ethambutol. Patients taking ethambutol 
should be instructed to discontinue the drug immediately at the 
onset of any visual symptoms and seek medical consult. All patients 
commencing treatment with ethambutol should have a baseline 
(pretreatment) ophthalmological examination. This comprises best 
corrected visual acuity, color vision, and visual field. These parameters 
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Case Report
Fig. 1: Fundus photo of, (a) Right eye, (b) left eye showing 
temporal pallor with the blurring of temporal margins (arrow) 
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should be monitored periodically (every 1-3 months) during the 
treatment period. Early detection of toxicity and withdrawal of 
ethambutol may be associated with good recovery.
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